Find in Library

Introduction AML and ALL differ substantially in response to therapy and course, and accurate differentiation of the two is fundamental to therapeutic decisions. Immunophenotyping helps in accurate differentiation between the two and various guidelines have been proposed regarding minimal screening antibody panel. Material and methods Eighty two cases of consecutive acute leukemias reporting to this hospital over a period of two years were included in the study. Peripheral blood smear, bone marrow aspirate and bone marrow biopsy were studied using morphology, cytochemical stains and relevant immunohistochemistry stains on selected biopsy specimens. FCM analysis was done on peripheral blood or bone marrow aspirate using Indian consensus screening  panel and our proposed minimal screening panel for comparison. Result Out of 82 cases of acute leukemias, by morphology alone 75.6%  and  by combined morphology and cytochemistry 93.90% of  cases were classified correctly into lymphoid and myeloid lineage. By immunophenotyping using proposed minimal screening panel 95.12% and Indian consensus minimal screening panel 93.90% of cases were classified into myeloid and lymphoid lineage. Conclusion Proposed minimal screening panel can be used as a substitute for Indian consensus minimal screening panel as it includes lineage specific  cytoplasmic antibodies and a lesser number of  monoclonal antibodies(mAbS).